

C1
75. (amended) A method for treating or preventing an autoimmune disorder, proliferative disorder, or infectious disease comprising administering to a mammal an anti-CD91 antibody that binds alpha (2) macroglobulin receptor in an amount effective to treat or prevent the autoimmune disorder, proliferative disorder, or infectious disease in the mammal.

C2
97. (amended) The method of claim 75, wherein the antibody modulates the interaction of the alpha (2) macroglobulin receptor with a heat shock protein.

C3
99. (amended) The method of claim 97, wherein the heat shock protein is gp96.

100. (amended) The method of claim 97, wherein the heat shock protein is Hsp70.

101. (amended) The method of claim 97, wherein the heat shock protein is Hsp90.

C4
104. (amended) The method of claim 75, wherein the method is a method for treating or preventing cancer.

105. (amended) The method of claim 104, wherein the anti-CD91 antibody modulates the interaction of alpha (2) macroglobulin receptor with an alpha (2) macroglobulin receptor ligand, in an amount effective to treat or prevent cancer in the mammal.

C5
107. (amended) The method of claim 75, wherein the method is a method for treating or preventing an infectious disease.

108. (amended) The method of claim 107, wherein the anti-CD91 antibody modulates the interaction of alpha (2) macroglobulin receptor with an alpha (2) macroglobulin receptor ligand.

C6
110. (amended) The method of claim 75, wherein the method is a method for treating or preventing an autoimmune disorder.

111. (amended) The method of claim 110, wherein the anti-CD91 antibody modulates the interaction of alpha (2) macroglobulin receptor with an alpha (2) macroglobulin receptor ligand.

121. (amended) The method of claim 75, 97, 104, 105, 107, 108, 110 or 111 wherein the anti-CD91 antibody is an agonist of the alpha (2) macroglobulin receptor.

122. (amended) The method of claim 75, 97, 104, 105, 107, 108, 110 or 111 wherein the anti-CD91 antibody is an antagonist of the alpha (2) macroglobulin receptor.

Add new claims 129, 130, 131 and 132 as follows:

129. (new) The method of any one of claims 75, 97, 104, 105, 107, 108, 110 or 111 wherein the mammal is a human.

130. (new) The method of claim 108 or 111, wherein the alpha (2) macroglobulin receptor ligand is a heat shock protein.

131. (new) The method of claim 130, wherein the heat shock protein is hsp70, hsp90, or gp96.

132. (new) The method of any one of claims 75, 97, 104, 105, 107, 108, 110 or 111, wherein the antibody is purified.

REMARKS

Claims 75 and 97-128 were pending in the instant application. By this amendment, claims 75, 97, 99-101, 104, 105, 107, 108, 110, 111, 121, and 122 have been amended, and new claims 129-132 have been added to clarify the invention, and claims 98, 102-103, 113-120, and 123-128 have been canceled without prejudice to Applicant's right to pursue the canceled claims in other applications,.